Administration of amifostine in the stage of remission induction can benefit the patients with hematological malignancy in autologous stem cell transplantation: a retrospective study

BACKGROUND: To investigate whether the administration of amifostine in the stage of remission induction can benefit patients with hematological malignancy in autologous stem cell transplantation (ASCT). METHODS: Two historical groups of patients who received prophylactic amifostine in the stage of r...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Min, Wu, Kefei, Chen, Pingping, Li, Pei, Xie, Yanhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798436/
https://www.ncbi.nlm.nih.gov/pubmed/35117881
http://dx.doi.org/10.21037/tcr-20-1366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798436/
https://www.ncbi.nlm.nih.gov/pubmed/35117881
http://dx.doi.org/10.21037/tcr-20-1366

Ejemplares similares